IRCT201111022704N2
Completed
Phase 2
The efficacy of rituximab for recalcitrant Pemphigus Vulgaris in the reduction of prednisolone dose
Vice-chancellor for Research of Tehran University of Medical Sciences0 sites40 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Pemphigus vulgaris.
- Sponsor
- Vice-chancellor for Research of Tehran University of Medical Sciences
- Enrollment
- 40
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with Pemphigus Vulgaris who are candidates for rituximab (failure to respond or frequent recurrences under long\-term (months to years) oral corticosteroids more than 10 mg daily with or without additional immunosuppressive therapy? or oral corticosteroids intolerance with or without short and long\-term oral coricosteroids side effects)
- •Exclusion criterion were: pregnancy and breast feeding?history of sensitization to murine protein?hepatitis B cariers?cardiac arrhythmias \& angina pectoris?high tumor burden?active infections
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 2
Clinical study for effectiveness of rituximab for acquired coagulopathyacquired coagulopathyJPRN-UMIN000024612Gunma University10
Completed
Not Applicable
A study of the efficacy and safety to rituximab in treating adult onset refractory nephrotic syndromeRefractory nephrotic syndromeJPRN-UMIN000021143Fujita Health University School of Medicine, Department of Nephrology10
Completed
Not Applicable
Efficacy and safety of rituximab for patients with severe rheumatic diseaseChildhood-onset severe rheumatic disease (systemic lupus erhythematosus, dermatomyositis, poly myositis, systemic sclerosis , mixed connective tissue disease, Sjogren's syndrome, anti-phospholipid syndrome)JPRN-UMIN000018376Yokohama City University Hospital Department of Pediatrics20
Active, not recruiting
Phase 1
Efficacy and safety of rituximab in the treatment of good prognosis microscopic polyangiitisEUCTR2018-000637-12-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)106
Active, not recruiting
Not Applicable
Efficacy and safety of rituximab in patients with rheumatoid arthritis - FIRSTRheumatoid arthritisMedDRA version: 8.1Level: PTClassification code 10039073Term: Rheumatoid arthritisEUCTR2006-001000-37-DERoche Pharma AG300